Background: HIV-infected patients have lower bone mineral density and a higher incidence
of fractures than the general population of the same age and sex. To assess the impact of …

Background: Different studies have reported an association between HIV infection,
antiretroviral therapies, and impaired bone metabolism, but data on their impact on fracture …

Abstract Background. Antiretrovirals (ARVs) affect bone density and turnover, but their effect
on risk of fractures and osteonecrosis of the femoral head is less understood. We …

Introduction Patients with HIV infection may have a higher prevalence of osteoporosis and
osteopenia, as well as an increased risk of bone fracture compared with non-HIV-infected …

Background: Whereas tenofovir (TDF) exposure has been associated with decreased bone
density, it remains unclear whether it is associated with increased risk of osteoporotic …

This study aims to determine what factors are associated with increased risk of fracture
among patients with HIV, in particular whether an important medication used to treat HIV …

Background: Bone mineral density declines by 2–6% within 1–2 years after initiation of
antiretroviral therapy (ART); however, it is uncertain whether this results in an immediate or …

Rates of osteoporosis and fracture may be increased in HIV but there are few UK data. Our
aim was to examine the prevalence of and risk factors for osteoporosis and fractures among …

Background: There is no clear consensus on the relationship between tenofovir (TDF) and
fracture risk because the studies published so far present contradictory findings. Study …

Objective To determine comparative fracture risk in HIV patients compared with uninfected
controls. Design A randomised cross-sectional study assessing bone mineral density (BMD) …